GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.13 CNY | +0.07% |
|
-1.12% | -13.47% |
| Sales 2024 * | 1.17B 161M | Sales 2025 * | 1.5B 208M | Capitalization | 5.98B 826M |
|---|---|---|---|---|---|
| Net income 2024 * | 315M 43.5M | Net income 2025 * | 422M 58.27M | EV / Sales 2024 * | 5.12 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.98 x |
| P/E ratio 2024 * |
19.1
x | P/E ratio 2025 * |
14.3
x | Employees | 931 |
| Yield 2024 * |
4.95% | Yield 2025 * |
4.95% | Free-Float | 44.62% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.07% | ||
| 1 week | -1.12% | ||
| Current month | -1.05% | ||
| 1 month | +4.28% | ||
| 3 months | -0.21% | ||
| 6 months | -23.04% | ||
| Current year | -13.47% |
1 week
14.05
14.90
1 month
13.7115.25
Current year
11.6516.46
1 year
11.6523.99
3 years
11.6523.99
5 years
11.6523.99
10 years
11.6523.99
| Managers | Title | Age | Since |
|---|---|---|---|
Han Jie Zheng
CEO | Chief Executive Officer | 61 | 98-12-31 |
Gui Xi Zhou
DFI | Director of Finance/CFO | 37 | 22-12-01 |
Ting Li
BRD | Director/Board Member | 41 | 19-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Liang
BRD | Director/Board Member | 52 | 22-06-29 |
Yi Ping Rui
BRD | Director/Board Member | 70 | 18-02-02 |
Han Jie Zheng
CEO | Chief Executive Officer | 61 | 98-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 14.13 | +0.07% | 1,651,940 |
| 24-05-23 | 14.12 | -4.47% | 2,898,740 |
| 24-05-22 | 14.78 | +1.16% | 2,275,120 |
| 24-05-21 | 14.61 | -0.14% | 2,334,580 |
| 24-05-20 | 14.63 | +2.38% | 3,251,370 |
End-of-day quote Shenzhen S.E., May 23, 2024
More quotes
Guangdong Taienkang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development and production of pharmaceutical products. The Company's businesses include agency operation, and sales of pharmaceutical products, medical devices and hygiene materials. The Company's main products include chemical medicines, external medicines, proprietary Chinese medicines, medical devices and hygiene materials. The Company is also engaged in the provision of medical technology services and technology transfer. The Company mainly conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.13
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.47% | 826M | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 301263 Stock
